Fusidic Acid
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Fusidic Acid: From Topical Antibacterial Use to Exposure Keratitis
One-Sentence Summary
Fusidic acid is an antibacterial. In South Africa it is registered only as topical creams and an ointment, and the registration records do not state an approved indication. The TxGNN model predicts it may be useful for exposure keratitis, but there are 0 clinical trials and only 1 publication (an unrelated ocular infection case series). This is a model prediction only and is not supported by direct evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration records provided (fusidic acid is an antibacterial) |
| Predicted New Indication | Exposure keratitis |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the evidence pack. Fusidic acid is an antibacterial that inhibits bacterial elongation factor G (EF-G). It is therefore plausible against Gram-positive ocular infections.
The link to exposure keratitis is weak. Exposure keratitis is mainly a surface-drying disorder caused by incomplete eyelid closure. Infection is a secondary complication, so an antibacterial could help only if a bacterial infection develops. The single literature hit is a Tsukamurella ocular case series. Its title gives no sign that fusidic acid was evaluated or used.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31246677 | 2019 | Case series | Cornea | Describes the clinical spectrum, risk factors, treatment and outcome of Tsukamurella species ocular infections, including the first report of an ocular implant infection after enucleation. Fusidic acid is not shown to have been evaluated. |
South Africa Market Information
All three registered products are topical (cream or ointment). None is an ophthalmic formulation.
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 45/13.4.1/0678 | Fucibet | Cream | Not stated in record |
| Reg. No. 45/13.4.1/0568 | Fucidin h | Cream | Not stated in record |
| Reg. No. G2090 (OM) | Fucidin H | Ointment | Not stated in record |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone. There are no clinical trials, and the only publication does not involve fusidic acid. The registered products are skin creams and an ointment, not eye preparations. Safety information from the SAHPRA PI is also missing.
To proceed, the following is needed:
- SAHPRA Professional Information (warnings and contraindications), which is a blocking gap for safety screening
- Mechanism of action data from DrugBank
- Confirmation that an ophthalmic-suitable formulation and route exist, since only topical skin products are registered
- Evidence that fusidic acid has actually been evaluated in exposure keratitis
Among the other predicted indications, otitis externa has the most support. It has a plausible anti-staphylococcal rationale, and a 1975 veterinary trial of a topical preparation containing Fucidin (with framycetin, nystatin and prednisolone) in dogs. However, that evidence is mostly veterinary and indirect, so it should be treated as a research question rather than a basis for a decision.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.